Worldwide, there are over a billion patients suffering from various neuro vestibular conditions like vertigo, migraine, concussion, ADHD etc. All these medical conditions have something in common apart from causing significant physical, psychological, social and emotional trauma. They all throw up manifestations in the eyes, in the form of pupil movements. Despite scientific evidence linking pupil movement to various neuro vestibular disorders, clinicians, so far have been largely relying on imaging technologies like CT and MRI to get diagnostic insights. Both these modalities are not widely available in emerging markets and come with great cost constraints.
Eye tracking based diagnosis can be nimble, accurate, easy to implement, easy to own and comes at a fraction of the cost of a CT or an MRI.
Cyclops Medtech is building diagnostic products for various neuro vestibular disorders based on eye tracking. Their first product, BalanceEye is a clinical diagnostic platform to determine the root cause for dizziness and balance disorders.
It’s important for clinicians to find out the root cause of dizziness. I’t helps clinicians to precisely identify the area of the lesion and thereby plan treatment accordingly. It is a 3 tiered solution comprising of a proprietary hardware, advanced image processing technology and cloud-based machine learning driven interpretation modules.
Within 14 months of the launch, they reached a mark of 100 installations. A large number of these installations are from tier 2 and tier 3 towns. Prior to launching BalanceEye, patients had to travel hundreds of kilometers to the nearest metro or a tier 1 city to get diagnosed. We have democratized the availability of state of the art diagnosis and made it extremely affordable. So far over 25,000 tests have been performed on our platform and many alarming conditions. Before BalanceEye, India had very few dizziness and balance assessment platforms and most were located in metros or tier 1 cities. Currently, the startup is a market leader in its space with close to 62% of the market share.